机构地区:[1]Center for Reproductive Medicine,International Peace Maternity and Child Health Hospital,Innovative Research Team of High-level Local Universities in Shanghai,School of Medicine,Shanghai Jiao Tong University,Shanghai 200030,1.Center for Reproductive Medicine,International Peace Maternity and Child Health Hospital,Innovative Research Team of High-level Local Universities in Shanghai,School of Medicine,Shanghai Jiao Tong University,Shanghai 200030,China [2]Institute of Neuroscience,State Key Laboratory of Neuroscience,Key Laboratory of Primate Neurobiology,CAS Center for Excellence in Brain Science and Intelligence Technology,Shanghai Institutes for Biological Sciences,Chinese Academy of Sciences,Shanghai 200031,China [3]Lingang Laboratory,Shanghai Research Center for Brain Science and Brain-Inspired Intelligence Technology,Shanghai 200031,China [4]Center for Reproductive Medicine,Ren Ji Hospital,School of Medicine,Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics,Shanghai Jiao Tong University,Shanghai 200127,China [5]The MOE Key Laboratory of Cell Proliferation and Differentiation,School of Life Sciences,Genome Editing Research Center,Peking University,Beijing 100871,China [6]Center for Reproductive Medicine,Shandong University,Jinan 250012,China [7]Center for Reproductive Medicine,Anhui Provincial Maternal and Child Health Hospital,Hefei 230001,China [8]Shenzhen Branch,Guangdong Laboratory for Lingnan Modern Agriculture,Genome Analysis Laboratory of the Ministry of Agriculture,Agricultural Genomics Institute at Shenzhen,Chinese Academy of Agricultural Sciences,Shenzhen 518000,China [9]Reproductive Medicine Center,Department of Obstetrics and Gynecology,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China
出 处:《Protein & Cell》2023年第6期416-432,共17页蛋白质与细胞(英文版)
基 金:supported by Chinese National Science and Technology major project R&D Program of China(2018YFC2000101);Strategic Priority Research Program of Chinese Academy of Science(XDB32060000);National Natural Science Foundation of China(Grant Nos.31871502,31901047,31925016,91957122,82021001,and 31922048);Basic Frontier Scientific Research Program of Chinese Academy of Sciences From 0 to 1 original innovation project(ZDBS-LYSM001);Shanghai Municipal Science and Technology Major Project(2018SHZDZX05);Shanghai City Committee of Science and Technology Project(18411953700,18JC1410100,19XD1424400 and 19YF1455100);Innovative Research Team of High-Level Local Universities in Shanghai(SHSMU-ZDCX20212200 and SHSMU-ZLCX20210200);International Partnership Program of Chinese Academy of Sciences(153D31KYSB20170059);Postdoctoral Science Foundation of China(2020M681417 and 2021T140684);Sailing Program of Shanghai(21YF1453000)(to J.H.).
摘 要:Approximately 140 million people worldwide are homozygous carriers of APOE4(ε4),a strong genetic risk factor for late onset familial and sporadic Alzheimer’s disease(AD),91%of whom will develop AD at earlier age than heterozygous carriers and noncarriers.Susceptibility to AD could be reduced by targeted editing of APOE4,but a technical basis for controlling the off-target effects of base editors is necessary to develop low-risk personalized gene therapies.Here,we first screened eight cytosine base editor variants at four injection stages(from 1-to 8-cell stage),and found that FNLS-YE1 variant in 8-cell embryos achieved the comparable base conversion rate(up to 100%)with the lowest bystander effects.In particular,80%of AD-susceptibleε4 allele copies were converted to the AD-neutralε3 allele in humanε4-carrying embryos.Stringent control measures combined with targeted deep sequencing,whole genome sequencing,and RNA sequencing showed no DNA or RNA off-target events in FNLS-YE1-treated human embryos or their derived stem cells.Furthermore,base editing with FNLS-YE1 showed no effects on embryo development to the blastocyst stage.Finally,we also demonstrated FNLS-YE1 could introduce known protective variants in human embryos to potentially reduce human susceptivity to systemic lupus erythematosus and familial hypercholesterolemia.Our study therefore suggests that base editing with FNLS-YE1 can efficiently and safely introduce known preventive variants in 8-cell human embryos,a potential approach for reducing human susceptibility to AD or other genetic diseases.
关 键 词:human embryo APOE4 disease-preventive mutations base editor
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...